• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中国济南奥密克戎BA.5毒株流行后小区中老年人群的流行病学和免疫学特征

Epidemiological and immunological characteristics of middle-aged and elderly people in housing estates after Omicron BA.5 wave in Jinan, China.

作者信息

Zhao Xin-Jing, Li Min, Zhang Sheng, Li Ke, Wei Wang-Qian, Chen Jin-Jin, Xu Qiang, Lv Chen-Long, Liu Ti, Wang Guo-Lin, Fang Li-Qun

机构信息

State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Sciences, Beijing, China.

Department of Epidemiology and Biotatistics, School of Public Health, Anhui Medical University, Hefei, China.

出版信息

Heliyon. 2024 Sep 25;10(19):e38382. doi: 10.1016/j.heliyon.2024.e38382. eCollection 2024 Oct 15.

DOI:10.1016/j.heliyon.2024.e38382
PMID:39398026
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11467590/
Abstract

A great number of COVID-19 patients was caused by Omicron BA.5 subvariant between December 2022 and January 2023 after the end of the zero-COVID-19 policy in China. In this study, we clarified the epidemiological and immunological characteristics of 457 enrolled middle-aged and elderly population in two housing estates after Omicron BA.5 wave. A total of 89.9 % (411/457) individuals have suffered Omicron BA.5 infection, among which 78.1 % (321/411) were symptomatic. The elderly patients were more likely to show fatigue and had longer symptomatic period than that of middle-aged patients post Omicron BA.5 infection. Omicron XBB and BA.2.86 subvariants extensively escaped the immunity elicited by Omicron BA.5 infection. The level of neutralizing antibody was mostly affected by vaccination doses rather than underlying disease status in these participants. It is very important to strengthen the epidemiological investigation and immune resistance assessment among elderly population for control of emerging SARS-CoV-2 variants.

摘要

在中国结束新冠疫情防控政策后,2022年12月至2023年1月期间,大量新冠病毒感染病例由奥密克戎BA.5亚变体引起。在本研究中,我们阐明了奥密克戎BA.5毒株感染高峰后两个居民区457名纳入研究的中老年人群的流行病学和免疫学特征。共有89.9%(411/457)的个体感染了奥密克戎BA.5,其中78.1%(321/411)出现症状。奥密克戎BA.5感染后,老年患者比中年患者更容易出现疲劳,且症状期更长。奥密克戎XBB和BA.2.86亚变体广泛逃逸了奥密克戎BA.5感染所诱导的免疫力。在这些参与者中,中和抗体水平主要受疫苗接种剂量影响,而非基础疾病状态。加强老年人群的流行病学调查和免疫抵抗力评估对于控制新出现的新冠病毒变种非常重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64a1/11467590/986938cb2ab1/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64a1/11467590/77cfe1b65d5f/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64a1/11467590/4116d039b4f3/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64a1/11467590/986938cb2ab1/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64a1/11467590/77cfe1b65d5f/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64a1/11467590/4116d039b4f3/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64a1/11467590/986938cb2ab1/gr3.jpg

相似文献

1
Epidemiological and immunological characteristics of middle-aged and elderly people in housing estates after Omicron BA.5 wave in Jinan, China.中国济南奥密克戎BA.5毒株流行后小区中老年人群的流行病学和免疫学特征
Heliyon. 2024 Sep 25;10(19):e38382. doi: 10.1016/j.heliyon.2024.e38382. eCollection 2024 Oct 15.
2
Epidemiological characteristics and antibody kinetics of elderly population with booster vaccination following both Omicron BA.5 and XBB waves in China.中国奥密克戎BA.5和XBB毒株流行后老年人群加强免疫接种的流行病学特征及抗体动力学
J Med Virol. 2024 May;96(5):e29640. doi: 10.1002/jmv.29640.
3
SARS-CoV-2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan-coronavirus fusion inhibitors.严重急性呼吸综合征冠状病毒2型奥密克戎XBB亚变体在老年人群中表现出增强的融合性和显著的免疫逃逸能力,但对泛冠状病毒融合抑制剂高度敏感。
J Med Virol. 2023 Mar;95(3):e28641. doi: 10.1002/jmv.28641.
4
Emerging Variants of SARS-CoV-2 and Novel Therapeutics Against Coronavirus (COVID-19)严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的新变种及针对冠状病毒(COVID-19)的新型疗法
5
Neutralization against Omicron subvariants after BA.5/BF.7 breakthrough infection weakened as virus evolution and aging despite repeated prototype-based vaccination.尽管基于原型的疫苗接种反复进行,但在 BA.5/ BF.7 突破性感染后,针对奥密克戎亚变种的中和作用随着病毒进化和老化而减弱。
Emerg Microbes Infect. 2023 Dec;12(2):2249121. doi: 10.1080/22221751.2023.2249121. Epub 2023 Sep 5.
6
Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study.新加坡一项全国性队列研究:SARS-CoV-2 感染和疫苗对有医疗记录的奥密克戎 BA.4、BA.5 和 XBB 再感染相关症状的保护免疫作用。
Lancet Infect Dis. 2023 Jul;23(7):799-805. doi: 10.1016/S1473-3099(23)00060-9. Epub 2023 Mar 13.
7
Low levels of neutralizing antibodies against XBB Omicron subvariants after BA.5 infection.感染 BA.5 后,针对 XBB 奥密克戎亚变种的中和抗体水平较低。
Signal Transduct Target Ther. 2023 Jun 19;8(1):252. doi: 10.1038/s41392-023-01495-4.
8
Cross-neutralizing antibody against emerging Omicron subvariants of SARS-CoV-2 in infection-naïve individuals with homologous BNT162b2 or BNT162b2(WT + BA.4/5) bivalent booster vaccination.感染前个体中针对 SARS-CoV-2 新兴奥密克戎亚变种的交叉中和抗体,同源 BNT162b2 或 BNT162b2(WT+BA.4/5) 二价加强针接种。
Virol J. 2024 Mar 21;21(1):70. doi: 10.1186/s12985-024-02335-9.
9
Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants.奥密克戎亚变体的中和敏感性、融合性和感染性。
Genome Med. 2022 Dec 29;14(1):146. doi: 10.1186/s13073-022-01151-6.
10
Relative vaccine protection, disease severity, and symptoms associated with the SARS-CoV-2 omicron subvariant BA.2.86 and descendant JN.1 in Denmark: a nationwide observational study.丹麦全国性观察研究:与 SARS-CoV-2 奥密克戎亚变体 BA.2.86 和后代 JN.1 相关的相对疫苗保护、疾病严重程度和症状。
Lancet Infect Dis. 2024 Sep;24(9):964-973. doi: 10.1016/S1473-3099(24)00220-2. Epub 2024 May 15.

本文引用的文献

1
SARS-CoV-2 reinfection broadens the antibody responses and promotes the phenotypic differentiation of virus-specific memory T cells in adolescents.SARS-CoV-2 再次感染可扩大抗体反应,并促进青少年病毒特异性记忆 T 细胞的表型分化。
J Med Virol. 2024 Aug;96(8):e29873. doi: 10.1002/jmv.29873.
2
Humoral and cellular immune responses following Omicron BA.2.2 breakthrough infection and Omicron BA.5 reinfection.奥密克戎BA.2.2突破性感染和奥密克戎BA.5再次感染后的体液免疫和细胞免疫反应。
iScience. 2024 Jun 15;27(7):110283. doi: 10.1016/j.isci.2024.110283. eCollection 2024 Jul 19.
3
Epidemiological characteristics and antibody kinetics of elderly population with booster vaccination following both Omicron BA.5 and XBB waves in China.
中国奥密克戎BA.5和XBB毒株流行后老年人群加强免疫接种的流行病学特征及抗体动力学
J Med Virol. 2024 May;96(5):e29640. doi: 10.1002/jmv.29640.
4
Neutralization escape by SARS-CoV-2 Omicron subvariant BA.2.86.奥密克戎变异株 BA.2.86 对 SARS-CoV-2 的中和逃逸
Vaccine. 2023 Nov 13;41(47):6904-6909. doi: 10.1016/j.vaccine.2023.10.051. Epub 2023 Oct 21.
5
Antigenicity and infectivity characterisation of SARS-CoV-2 BA.2.86.新型冠状病毒BA.2.86的抗原性和感染性特征
Lancet Infect Dis. 2023 Nov;23(11):e457-e459. doi: 10.1016/S1473-3099(23)00573-X. Epub 2023 Sep 19.
6
Antibody neutralisation of emerging SARS-CoV-2 subvariants: EG.5.1 and XBC.1.6.新兴的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)亚变体的抗体中和作用:EG.5.1和XBC.1.6
Lancet Infect Dis. 2023 Oct;23(10):e397-e398. doi: 10.1016/S1473-3099(23)00555-8. Epub 2023 Sep 11.
7
Clinical characteristics of abruptly increased paediatric patients with Omicron BF.7 or BA.5.2 in Beijing.北京 Omicron BF.7 或 BA.5.2 亚株感染儿童患者突然增多的临床特征。
Virol J. 2023 Sep 8;20(1):209. doi: 10.1186/s12985-023-02177-x.
8
Neutralization against Omicron subvariants after BA.5/BF.7 breakthrough infection weakened as virus evolution and aging despite repeated prototype-based vaccination.尽管基于原型的疫苗接种反复进行,但在 BA.5/ BF.7 突破性感染后,针对奥密克戎亚变种的中和作用随着病毒进化和老化而减弱。
Emerg Microbes Infect. 2023 Dec;12(2):2249121. doi: 10.1080/22221751.2023.2249121. Epub 2023 Sep 5.
9
SARS-CoV-2-specific antibody and T-cell immunity in convalescents after infection wave in Beijing in late 2022.2022 年末北京感染浪潮后康复者体内的 SARS-CoV-2 特异性抗体和 T 细胞免疫。
J Infect. 2023 Nov;87(5):413-419. doi: 10.1016/j.jinf.2023.08.010. Epub 2023 Aug 29.
10
A Comparative Study of Immunogenicity, Antibody Persistence, and Safety of Three Different COVID-19 Boosters between Individuals with Comorbidities and the Normal Population.合并症患者与正常人群中三种不同新冠病毒加强针的免疫原性、抗体持久性及安全性的比较研究
Vaccines (Basel). 2023 Aug 17;11(8):1376. doi: 10.3390/vaccines11081376.